Overweight and obese patients who took the weight-loss drug Qsymia, which combines phentermine and topiramate extended release, were 70.5% to 78.7% less likely than those in the placebo group to develop type 2 diabetes, a study found. Patients in the Qsymia arm also showed greater weight loss at 108 weeks compared with the controls, researchers wrote in Diabetes Care.

Related Summaries